Abstract:The complement system plays a key role in opsonization and immune clearance of engineered nanoparticles. Understanding the efficiency, inter-subject, and inter-strain differences of complement opsonization in preclinical species can help with translational nanomedicine development and improve our ability to model complement response in humans. Dextran-coated superparamagnetic iron oxide (SPIO) nanoparticles and a wide range of non-magnetic iron oxide nanoparticle formulations are widely used in magnetic resonance imaging and as clinically approved iron supplements. Previously we found that opsonization of SPIO nanoworms (NW) with the third complement protein (C3) proceeds mostly via the alternative pathway in humans, and via the lectin pathway in mice. Here, we studied the pathway and efficiency of opsonization of 106 nm SPIO NW with C3 in different preclinical species and commonly used laboratory strains. In sera of healthy human donors (n = 6), C3 opsonization proceeded exclusively through the alternative pathway. On the other hand, the C3 opsonization in dogs (6 breeds), rats (4 strains) and mice (5 strains) sera was either partially or completely dependent on the complement Ca2+-sensitive pathways (lectin and/or classical). Specifically, C3 opsonization in sera of Long Evans rat strain, and mouse strains widely used in nanomedicine research (BALB/c, C57BL/6 J, and A/J) was only through the Ca2+-dependent pathways. Dogs and humans had the highest between-subject variability in C3 opsonization levels, while rat and mouse sera showed the lowest between-strain variability. Furthermore, using a panel of SPIO nanoparticles of different sizes and dextran coatings, we found that the level of C3 opsonization (C3 molecules per milligram Fe) in human sera was lower than in animal sera. At the same time, there was a strong predictive value of complement opsonization in dog and rat sera; nanoparticles with higher C3 deposition in animals showed higher deposition in humans, and vice versa. Notably, the opsonization decreased with decreasing size in all sera. The studies highlight the importance of the consideration of species and strains for predicting human complement responses (opsonization) towards nanomedicines.

Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts

Complement Proteins Bind to Nanoparticle Protein Corona and Undergo Dynamic Exchange in Vivo.

Immunoglobulin Deposition on Biomolecule Corona Determines Complement Opsonization Efficiency of Preclinical and Clinical Nanoparticles

Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles

Complement opsonization of nanoparticles: Differences between humans and preclinical species

Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement Activation

In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms

Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake

Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins

Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking

Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation.

The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance

Formation of Protein Corona on Nanoparticle Affects Different Complement Activation Pathways Mediated by C1q

Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro

Influence of PEG Chain on the Complement Activation Suppression and Longevity in Vivo Prolongation of the PCL Biomedical Nanoparticles

Complement-dependent uptake of nanoparticles by blood phagocytes: brief overview and perspective

The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes

Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines

CH(50): a revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction

C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells